Expertise in
34
conditions

Dr. James M. Foran

Hematology Oncology | Hematology | Oncology
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
31 Years of Experience
Expertise in
34
conditions
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Foran is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Foran has been practicing medicine for over 31 years is highly rated in 34 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Foran is currently accepting new patients.

His clinical research consists of co-authoring 172 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Mayo Clinic
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO

Locations

MAYO CLINIC JACKSONVILLE
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Samalizumab, BI-836858, Daunorubicin, Cytarabine, Azacitidine, AG-221, Entospletinib, Decitabine, Pevonedistat, AG-120, Gilteritinib, AZD5153, Venetoclax, TP-0903, AZD5991
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Enrollment Status: Terminated
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine
Study Phase: Phase 3
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 14 Less Clinical Trials

172 Total Publications

Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasms.
Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasms.
Journal: Leukemia research
Published: April 03, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Sikander Ailawadhi
Hematology Oncology | Hematology | Oncology
Expertise in
25
conditions
Dr. Sikander Ailawadhi
Hematology Oncology | Hematology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 mi)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sikander Ailawadhi is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Ailawadhi is highly rated in 25 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ailawadhi is currently accepting new patients.

Expertise in
14
conditions
Dr. Asher A. Chanan-Khan
Hematology Oncology | Hematology | Oncology
Expertise in
14
conditions
Dr. Asher A. Chanan-Khan
Hematology Oncology | Hematology | Oncology
4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 mi)
904-953-2000
Languages Spoken:
English

Asher Chanan-Khan is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Chanan-Khan is highly rated in 14 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
12
conditions
Dr. Yanyan T. Lou
Hematology Oncology | Hematology | Oncology
Expertise in
12
conditions
Dr. Yanyan T. Lou
Hematology Oncology | Hematology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 mi)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yanyan Lou is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Lou is highly rated in 12 conditions, according to our data. Her top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy. Dr. Lou is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Foran's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 22 Advanced Conditions
View All 90 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile